Tags

Type your tag names separated by a space and hit enter

Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
J Alzheimers Dis. 2018; 65(3):793-806.JA

Abstract

Late-life depression, even when of subsyndromal severity, has shown strong associations with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Preclinical studies have suggested that serotonin selective reuptake inhibitors (SSRIs) can attenuate amyloidogenesis. Therefore, we aimed to investigate the effect of SSRI medication on amyloidosis and grey matter volume in subsyndromal depressed subjects with MCI and AD during an interval of two years. 256 cognitively affected subjects (225 MCI/ 31 AD) undergoing [18F]-AV45-PET and MRI at baseline and 2-year follow-up were selected from the ADNI database. Subjects with a positive depression item (DEP(+); n = 73) in the Neuropsychiatric Inventory Questionnaire were subdivided to those receiving SSRI medication (SSRI(+); n = 24) and those without SSRI treatment (SSRI(-); n = 49). Longitudinal cognition (Δ-ADAS), amyloid deposition rate (standardized uptake value, using white matter as reference region (SUVRWM), and changes in grey matter volume were compared using common covariates. Analyses were performed separately in all subjects and in the subgroup of amyloid-positive subjects. Cognitive performance in DEP(+)/SSRI(+) subjects (Δ-ADAS: -5.0%) showed less deterioration with 2-year follow-up when compared to DEP(+)/SSRI(-) subjects (Δ-ADAS: +18.6%, p < 0.05), independent of amyloid SUVRWM at baseline. With SSRI treatment, the progression of grey matter atrophy was reduced (-0.9% versus -2.7%, p < 0.05), notably in fronto-temporal cortex. A slight trend towards lower amyloid deposition rate was observed in DEP(+)/SSRI(+) subjects versus DEP(+)/SSRI(-). Despite the lack of effect to amyloid PET, SSRI medication distinctly rescued the declining cognitive performance in cognitively affected patients with depressive symptoms, and likewise attenuated grey matter atrophy.

Authors+Show Affiliations

Department of Nuclear Medicine, University of Munich, Germany.Department of Nuclear Medicine, University of Munich, Germany.Department of Statistics, University of Munich, Germany.Department of Nuclear Medicine, University of Munich, Germany.Department of Nuclear Medicine, University of Munich, Germany.Department of Nuclear Medicine, University of Munich, Germany.Department of Nuclear Medicine, University of Munich, Germany.Department of Psychiatry, University of Munich, Germany.Department of Radiology, Kindai University Faculty of Medicine, Osakasayama City, Osaka, Japan.Department of Nuclear Medicine, University of Munich, Germany.Department of Nuclear Medicine, University of Munich, Germany. Department of Nuclear Medicine, Inselspital, University Hospital Bern, Switzerland.No affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

30010116

Citation

Brendel, Matthias, et al. "Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but Not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients With Depressive Symptoms." Journal of Alzheimer's Disease : JAD, vol. 65, no. 3, 2018, pp. 793-806.
Brendel M, Sauerbeck J, Greven S, et al. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms. J Alzheimers Dis. 2018;65(3):793-806.
Brendel, M., Sauerbeck, J., Greven, S., Kotz, S., Scheiwein, F., Blautzik, J., Delker, A., Pogarell, O., Ishii, K., Bartenstein, P., & Rominger, A. (2018). Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms. Journal of Alzheimer's Disease : JAD, 65(3), 793-806. https://doi.org/10.3233/JAD-170387
Brendel M, et al. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but Not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients With Depressive Symptoms. J Alzheimers Dis. 2018;65(3):793-806. PubMed PMID: 30010116.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms. AU - Brendel,Matthias, AU - Sauerbeck,Julia, AU - Greven,Sonja, AU - Kotz,Sebastian, AU - Scheiwein,Franziska, AU - Blautzik,Janusch, AU - Delker,Andreas, AU - Pogarell,Oliver, AU - Ishii,Kazunari, AU - Bartenstein,Peter, AU - Rominger,Axel, AU - ,, PY - 2018/7/17/pubmed PY - 2019/8/20/medline PY - 2018/7/17/entrez KW - Alzheimer’s disease KW - SSRI KW - amyloid PET KW - depressive symptoms KW - grey matter volume SP - 793 EP - 806 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 65 IS - 3 N2 - Late-life depression, even when of subsyndromal severity, has shown strong associations with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Preclinical studies have suggested that serotonin selective reuptake inhibitors (SSRIs) can attenuate amyloidogenesis. Therefore, we aimed to investigate the effect of SSRI medication on amyloidosis and grey matter volume in subsyndromal depressed subjects with MCI and AD during an interval of two years. 256 cognitively affected subjects (225 MCI/ 31 AD) undergoing [18F]-AV45-PET and MRI at baseline and 2-year follow-up were selected from the ADNI database. Subjects with a positive depression item (DEP(+); n = 73) in the Neuropsychiatric Inventory Questionnaire were subdivided to those receiving SSRI medication (SSRI(+); n = 24) and those without SSRI treatment (SSRI(-); n = 49). Longitudinal cognition (Δ-ADAS), amyloid deposition rate (standardized uptake value, using white matter as reference region (SUVRWM), and changes in grey matter volume were compared using common covariates. Analyses were performed separately in all subjects and in the subgroup of amyloid-positive subjects. Cognitive performance in DEP(+)/SSRI(+) subjects (Δ-ADAS: -5.0%) showed less deterioration with 2-year follow-up when compared to DEP(+)/SSRI(-) subjects (Δ-ADAS: +18.6%, p < 0.05), independent of amyloid SUVRWM at baseline. With SSRI treatment, the progression of grey matter atrophy was reduced (-0.9% versus -2.7%, p < 0.05), notably in fronto-temporal cortex. A slight trend towards lower amyloid deposition rate was observed in DEP(+)/SSRI(+) subjects versus DEP(+)/SSRI(-). Despite the lack of effect to amyloid PET, SSRI medication distinctly rescued the declining cognitive performance in cognitively affected patients with depressive symptoms, and likewise attenuated grey matter atrophy. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/30010116/Serotonin_Selective_Reuptake_Inhibitor_Treatment_Improves_Cognition_and_Grey_Matter_Atrophy_but_not_Amyloid_Burden_During_Two_Year_Follow_Up_in_Mild_Cognitive_Impairment_and_Alzheimer's_Disease_Patients_with_Depressive_Symptoms_ L2 - https://content.iospress.com/openurl?genre=article&amp;id=doi:10.3233/JAD-170387 DB - PRIME DP - Unbound Medicine ER -